24-h Energy Expenditure and Anti-obesity Medication

NCT07041983 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial tests how a medication affects daily calorie burning in adults with obesity over a 6-month period.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 30 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2025-07 · est. completion 2026-12

Where 1 site · Italy

What this study is testing ClinicalTrials.gov NCT07041983 ↗

Description as written by the study sponsor.

This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)

Treatments tested

anti obesity medication Drug

Patients with obesity or overweight, with at least one weight-related comorbidity who are expected to start treatment with Semaglutide (Wegovy) or Terzepatide (Mounjaro) at enrolment will be eligible to enrol into the study. Patients will be treated and observed according to normal clinical practice. Participation in this study does not limit the physicians' clinical decision making as to the most appropriate treatment for the patient during the course of the study

Main thing measured	change in 24h energy expenditure after 6 months of treatment
Sponsor	University of Pisa
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07041983 ↗